Table 3.
Prevalence of the TMPRSS2:ERG gene fusion in men with prostate cancer from studies in the meta-analysis
| Overall Fusion Analysis | Fusion Mechanism Analysis | |||
|---|---|---|---|---|
|
|
||||
| Characteristic | Sample Size | Prevalence Fusion Positive |
Sample Size | Prevalence Fusion- by-Deletiona |
| Overall | 10,779 | 46.9% | 1,390 | 63.7% |
| Assay b | ||||
| FISH | 3,146 | 42.4% | 1,008 | 62.6% |
| RT-PCR | 1,311 | 52.2% | N/A | N/A |
| IHC | 4,763 | 51.8% | N/A | N/A |
| Cohort Continent b c | ||||
| Asia | 837 | 23.4% | 67 | 61.2% |
| Europe | 4,926 | 53.6% | 380 | 63.9% |
| North America | 3,217 | 47.6% | 530 | 63.2% |
| Tissue Assayed | ||||
| Biopsy | 611 | 43.0% | 190 | 60.0% |
| Lymph Node | 71 | 59.2% | 0 | N/A |
| RP Specimen | 9,220 | 48.6% | 1,035 | 63.1% |
| TURP Specimen | 803 | 29.8% | 165 | 71.5% |
| Urine | 74 | 36.5% | 0 | N/A |
Abbreviations: FISH – Fluorescence In Situ Hybridization; IHC – Immunohistochemistry; RP – Radical Prostatectomy; RT-PCR – Reverse Transcription Polymerase Chain Reaction; TURP – Transurethral Resection of the Prostate
a
Among those for whom fusion mechanism was determined
b
In radical prostatectomy specimens only
c
Excludes cohorts with patients from multiple regions or areas outside those listed